Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Kazia Therapeutics Ltd
KZIA
Healthcare
Biotechnology
Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for...
several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:KZIA)
New Post
View:
Posts & Comments
Threaded Posts
(276)
•••
whytestocks
X
Post by
whytestocks
on Oct 02, 2024 10:32am
Kazia Therapeutics Announces Presentation of Promising Phase
News; $KZIA Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Sep 23, 2024 7:45pm
Kazia Therapeutics Announces Presentation of EVT801 Clinical
NEWS: $KZIA Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumKazia Therapeutics Announces Presentation of EVT801 Clinical Data at
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Jul 11, 2024 10:17am
US Stocks Edge Higher; Inflation Slows To 3% In June | Benzi
Breaking News: $KZIA US Stocks Edge Higher; Inflation Slows To 3% In June | BenzingaU.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 0.1% on Thursday.Following
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Jul 11, 2024 10:01am
Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20
NEWS: $KZIA Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket | BenzingaShares of WD-40 Company (NASDAQ:WDFC) rose sharply in today@s pre-market trading after the
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Jul 10, 2024 10:01am
Kazia Therapeutics Announces Phase II/III Clinical Trial Res
JUST IN: $KZIA Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in GlioblastomaKazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Jun 27, 2024 12:00pm
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AN
BREAKING NEWS: $KZIA KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCERKAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 09, 2022 7:00am
New Press Release - KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
SYDNEY, Nov. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 02, 2022 7:15am
New Press Release - Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
LONDON, UK / ACCESSWIRE / November 2, 2022 / Kazia Therapeutics' Q123 cash flow report provided an update on the company's financial position and business progress. While the quarter was dominated by lead asset paxalisib hitting a roadblock (failing to graduate to stage two of the GBM AGILE study...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 28, 2022 2:46pm
KZIA .... I will be pi$$ed if this runs
Grrrrrrrrr
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 28, 2022 12:37pm
KZIA ....Looks like the MM that shorted the cr8p out of this
yesterday ....is slowly picking away Me ...no position Cheers !
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Oct 27, 2022 12:11pm
RE:KZIA ...This would have to bust thru ~ $1.03 for me to.....
I forgot to mention that the volume would have to increase dramatically also !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2022 12:09pm
KZIA ...This would have to bust thru ~ $1.03 for me to.....
increase my position ; ) Just leting u know Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2022 10:42am
KZIA .....I was just going over the LT Chart
This certainly has a propensity to trade big volumes in the past There has to be a reason for this volume.... I'm going to take a small position here sub -$1.00 For my buddy Justin..... Justin
...more
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2022 10:34am
KZIA ..Wow...That is an exercise in How to Fack Everyone!
You see this on NASDAQ all the time Green to red moves on volume Feel for the chasers
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2022 9:30am
KZIA ....up in early a.m trading
on watch
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing